Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02080390 · ClinicalTrials.gov registry record
Strain Imaging in Breast Cancer Patients Receiving Trastuzumab
A clinical trial of Her 2 Positive Breast Cancer, sponsored by University of Florida.
- Completed
- Registry status
- 25
- Enrollment target
- 1
- Study location
NCT02080390 is a study of Her 2 Positive Breast Cancer that has completed, run by University of Florida. The registered enrollment target is 25 participants, below the 237-participant average among 3 other Her 2 Positive Breast Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02080390, a study of Her 2 Positive Breast Cancer, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this happens. The investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.
Conditions Studied
Interventions
- PROCEDURE Transthoracic echocardiogram (ultrasound)
Study Locations (1)
Florida
- Univerisity of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2014-09 |
| Est. Completion | 2019-02-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02080390
The ClinicalTrials.gov registry entry for NCT02080390 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 237-participant average among 3 other Her 2 Positive Breast Cancer trials with a reported enrollment target (89% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Her 2 Positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Transthoracic echocardiogram (ultrasound) is the first listed.
NCT02080390 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02080390 about?
NCT02080390 is a clinical study titled "Strain Imaging in Breast Cancer Patients Receiving Trastuzumab". The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this h...
What is the current status of trial NCT02080390?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2014-09. Estimated completion is 2019-02-14.
What conditions does trial NCT02080390 study?
This clinical trial studies the following conditions: Her 2 Positive Breast Cancer.
What interventions are being tested in trial NCT02080390?
The interventions under investigation include: Transthoracic echocardiogram (ultrasound) (PROCEDURE).
Who is sponsoring clinical trial NCT02080390?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02080390 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Her 2 Positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
ACTIVE NOT RECRUITING · Phase 2
-
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
ACTIVE NOT RECRUITING · Phase 2
-
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.